Biotech news

Reset all filters
Geography
Company
Refine search
Compulsory licences: Working in the public interest
Asia
Parties can apply for a compulsory licence in India on several grounds, including that the invention is not worked in the country. Neeti Wilson of Anand and Anand explores the issue further.   27 October 2015
Amgen v Sandoz: The biosimilars saga continues
Americas
Despite the US Court of Appeals for the Federal Circuit’s ruling in Amgen v Sandoz, significant uncertainty concerning two key provisions of the BPCIA remains, as Steve Coyle and Leslie-Anne Maxwell of Cantor Colburn describe.   27 October 2015
Luc enters depression treatment IP licensing deal with Novartis
Americas
Biotechnology company Luc Therapeutics has agreed to licence its intellectual property covering its depression treatment to Novartis, stating that it will accelerate its programme into how to help people living with psychiatric diseases.   23 October 2015
Americas
Very few members of Congress are informed about the trajectory of section 101 and instead lawmakers are looking at ‘trolls’ and other patent issues, according to a counsel at the Biotechnology Industry Organization.   23 October 2015
Biotech
The life sciences sector in the UK is booming, as delegates at October’s BIA forum heard. Jane Wainwright of Potter Clarkson reports.   22 October 2015
Americas
The US Court of Appeals for the Federal Circuit has declined to hear the Amgen v Sandoz ‘patent dance’ dispute en banc.   19 October 2015
Americas
A counsel for pharmaceutical company Eli Lilly has said that recent court decisions, including Ariosa v Sequenom, will create a bar to innovation.   16 October 2015
Americas
The US’s consul general in Rio de Janeiro has urged the US and Brazilian governments to work together to tackle the long delay in biotechnology-related patents being granted at Brazil’s intellectual property office.   15 October 2015
Americas
Law firm BakerHostetler has hired Allen Sokal as counsel in the firm’s intellectual property group in Washington, DC.   15 October 2015
Biotech
The Dutch lobby to amend Directive 98/44/EC on the legal protection of biotechnological inventions will severely damage the ability of the biotech sector to innovate—and for no tangible reason, says Annemiek Verkamman of HollandBIO.   15 October 2015